Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol APOA5 contributors: mct - updated : 08-04-2022
HGNC name apolipoprotein A-V
HGNC id 17288
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
4 polyA site 1935 - 366 - 2020 33753020
3 polyA site 1881 - 366 liver 2020 33753020
3 - 1911 - 366 - 2020 33753020
EXPRESSION
Type restricted
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Digestiveintestinelarge intestinecolon moderately Homo sapiens
 intestinesmall intestineduodenum moderately Homo sapiens
 liver     Homo sapiens
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
a N terminal signal peptide
secondary structure several amphipatic helical domains
isoforms Precursor
HOMOLOGY
Homologene
FAMILY
CATEGORY regulatory
SUBCELLULAR LOCALIZATION extracellular
    intracellular
intracellular,cytoplasm,organelle,endoplasmic reticulum
intracellular,cytoplasm,organelle,Golgi
intracellular,cytoplasm,organelle,endosome
text plasma protein
basic FUNCTION
  • important determinant of plasma triglycride level, that
  • may function intracellularly to modulate hepatic VLDL synthesis and/or secretion
  • play an important role in determining plasma triglyceride concentrations
  • is an acute phase protein associated with HDL, which is independent of its effects on TG metabolism.
  • APOA5 is a key regulator of plasma triglyceride and have multifunction in several target organs
  • APOA5 may potentially be a pivotal target for right ventricular (RV) failure and fibrosis secondary of pulmonary hypertension (PH)
  • APOA5 is involved in fructose-induced metabolic dysregulation and associated hepatic steatosis
  • CELLULAR PROCESS cell organization/biogenesis
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • estrogen lowers triglyceride via regulating hepatic APOA5 expression
  • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s) HLP5
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional     --over  
    during liver regeneration
    Susceptibility
  • to coronary artery disease
  • to higher plama triglycerides
  • to familial combined hyperlipidemia
  • to variation of BMI and obesity risk in both men and women
  • to metabolic syndrome
  • Variant & Polymorphism SNP
  • SNP1, SNP2, SNP3, polymorphism T1131>C and S19>W variant, c.553G>T, associated with hypertriglyceridemia
  • S19W polymorphism is likely to be functional and explain the strong association of this variant with plasma triglycerides
  • variant c.553G > T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels
  • 1131T>C SNP, modulates the effect of fat intake on BMI and obesity risk in both men and women
  • APOA5 rs662799 is associated with metabolic syndrome
  • APOA5 variants cause hypertriglyceridemia
  • hypertriglyceridemic patients carrying the APOA5 -1131T>C polymorphism exhibited increased atherogenic LDL levels and arterial stiffness, probably due to an effect of the -1131T>C polymorphism on apoA5 concentrations
  • Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS